BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With recent accelerated approval wins\, positive clinical tria
 l readouts\, progression through clinical pipelines and exciting mergers 
 and acquisitions\, it has certainly been an industry-defining year for th
 e rare and genetic renal space.\n\nIn the context of rapid progress and a
  mounting desire to propel game-changing novel therapies that will add to
  the arsenal of therapeutic options for patients\, the 4th Rare and Genet
 ic Kidney Disease Drug Development Summit returns to Boston. This unique 
 event for the industry\, academic KOL\, and patient advocacy nephrology c
 ommunity provides an unrivalled opportunity to discuss acceleration of cl
 inical advancements in orphan kidney disease populations.\n\nThis year's 
 meeting brings together 30+ expert speakers\, a two-tracked pre-conferenc
 e workshop day and new content on podocyte biology\, tissue bioengineerin
 g of kidney tissue models\, market access strategies\, as well as pricing
  and reimbursement conversations\, across a breadth of rare renal therape
 utic areas including FSGS\, PKD\, Alport Syndrome and IgAN to name but a 
 few!\n\nURLs:Website:&nbsp\;https://go.evvnt.com/2595572-0?pid=185Tickets
 :&nbsp\;https://go.evvnt.com/2595572-2?pid=185Brochure:&nbsp\;https://go.
 evvnt.com/2595572-3?pid=185\n\nPrices:Conference + Discover and Translati
 onal Workshops - Industry: USD 4197.00\,Conference + Clinical and Market 
 Access Workshops - Industry: USD 4197.00\,Conference Only - Industry: USD
  2999.00\,Conference + Discover and Translational Workshops - Academic: U
 SD 3597.00\,Conference + Clinical and Market Access Workshops - Academic:
  USD 3597.00\,Conference Only - Academic: USD 2599.00\,Conference + Disco
 ver and Translational Workshops - Vendor: USD 5097.00\,Conference + Clini
 cal and Market Access Workshops - Vendor: USD 5097.00\,Conference Only - 
 Vendor: USD 3699.00\n\nSpeakers:&nbsp\;Robbie McCarthy\, USA General Mana
 ger\, Advicenne S.A.\, B. Andre Weinstock\, Research Director\, Alport Sy
 ndrome Foundation\, Stephen Olson\, Senior Medical Director\, Early Clini
 cal Development\, AstraZeneca\, Weining Lu\, Associate Professor\, Boston
  University\, Laurence H. Beck Jr.\, Nephrologist and David J. Salant MD 
 Professor of Nephrology\, Boston University\, Richard Watt\, Associate Pr
 ofessor and Chief Scientific Officer\, Brigham Young University and REVIT
 ALE Pharma\, Achim Obergfell\, Global Medical Head Nephrology\, CSL Vifor
 \, Doug Paul\, VP Commercial Strategy and Founder\, Cypress BioPharma\, S
 umit Aggarwal\, President and Chief Executive Officer\, Eloxx Pharmaceuti
 cals\, Balaji Karthick Subramanian\, Assistant Professor of Medicine\, Ha
 rvard Medical School\, Dongwon Lee\, Assistant Professor of Pediatrics\, 
 Harvard Medical School\, Friedhelm Hildebrandt\, Professor of Pediatrics\
 , Nephrology\, Harvard Medical School\, Dario Lemos\, Assistant Professor
  of Medicine\, Harvard Medical School and Brigham and Women's Hospital\, 
 Laurel Damashek\, Executive Director\, International Society of Glomerula
 r Disease\, Neel Anand\, Senior Vice President\, Research and Drug Discov
 ery\, Kezar Life Sciences\, Susan Limb\, Vice President\, Clinical Scienc
 e\, Maze Therapeutics\, Adele Rowley\, Chief Scientific Officer\, Mironid
  Ltd.\, David Feldman\, Senior Medical Project Director\, National Kidney
  Foundation\, William Smoyer\, VP\, Nationwide Children's Hospital\, Josh
 ua Tarnoff\, Chief Executive Officer\, NephCure Kidney International\, Je
 e Yeon Kim\, Associate Clinical Research Medical Director (Renal)\, Novar
 tis AG\, Srini Srinivas\, Senior Medical Director\, Renal Diseases and Ev
 idence Generation Lead\, Novartis AG\, Gerard Honig Associate Director\, 
 Biomarker Research\, Otsuka Pharmaceutical Development and Commercializat
 ion\, Inc\, Michelle M. Richardson Director\, Patient-Centered Research a
 nd Clinical Outcome Assessments\, Otsuka Pharmaceuticals Development and 
 Commercialization\, Inc\, Pille Harrison\, VP Clinical Development\, Pure
 spring Therapeutics\, John Seman\, Chief Executive Officer\, REVITALE Pha
 rma\, Chris Smith\, President and Chief Executive Officer\, SmithSolve LL
 C\, Rachel McComb\, Senior Clinical Operations Progam\, Lead Rare GI2\, T
 akeda Pharmaceutical\, Kevin Fowler\, Principal\, The Voice of the Patien
 t\, Sean Eddy\, Associate Research Scientist\, NEPTUNE Match Molecular Pr
 ofiling Lead\, University of Michigan\, Eloise Salmon\, Clinical Assistan
 t Professor\, University of Michigan\, Kerry Cooper\, Senior Vice Preside
 nt Medical Affairs\, Vera Therapeutics\, Alex Duncan\, Chief Scientific O
 fficer\, Walden Biosciences\, Allen Davidoff\, Chief Executive Officer\, 
 XORTX Therapeutics Inc.\n\nCategory:&nbsp\;Conferences | Science\, Health
  and Medicine\n\nDate and Time:&nbsp\;10th December 2024 at 8:00 am to 12
 th December 2024 at 5:30 pm\n\nVenue details:&nbsp\;Revere Hotel\, 200 St
 uart Street\, Boston\, Massachusetts\, 02116\, United States\n
DTEND:20241212T173000
DTSTAMP:20260512T225918Z
DTSTART:20241210T080000
LOCATION:Revere Hotel\, 200\, Stuart Street\, Boston\, Massachusetts\, 021
 16\,
SEQUENCE:0
SUMMARY:With recent accelerated approval wins\, positive clinical trial re
 adouts\, progression through clinical pipelines and exciting mergers and 
 acquisitio...
UID:e77083a5-02bb-4b7c-80ae-157b9cfeb0d0
END:VEVENT
END:VCALENDAR